 Joshua Gowin
Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Reward | 10 | 2025 | 247 | 3.300 |
Why?
| | Alcoholism | 10 | 2024 | 817 | 2.330 |
Why?
| | Delay Discounting | 4 | 2025 | 29 | 2.100 |
Why?
| | Alcohol Drinking | 10 | 2025 | 826 | 2.060 |
Why?
| | Neuroimaging | 5 | 2024 | 289 | 1.810 |
Why?
| | Emotions | 8 | 2026 | 578 | 1.810 |
Why?
| | Ethanol | 9 | 2025 | 627 | 1.640 |
Why?
| | Brain | 11 | 2026 | 2933 | 1.610 |
Why?
| | Substance-Related Disorders | 11 | 2022 | 1094 | 1.560 |
Why?
| | Risk-Taking | 5 | 2020 | 328 | 1.540 |
Why?
| | Amygdala | 3 | 2026 | 198 | 1.460 |
Why?
| | Brain Mapping | 8 | 2026 | 536 | 1.440 |
Why?
| | Mental Disorders | 4 | 2026 | 1168 | 1.300 |
Why?
| | Magnetic Resonance Imaging | 16 | 2026 | 3863 | 1.280 |
Why?
| | Binge Drinking | 3 | 2020 | 44 | 1.250 |
Why?
| | Aggression | 6 | 2015 | 179 | 1.170 |
Why?
| | Gambling | 2 | 2020 | 30 | 1.140 |
Why?
| | Cerebral Cortex | 4 | 2019 | 464 | 1.090 |
Why?
| | Craving | 4 | 2020 | 39 | 0.910 |
Why?
| | Verbal Learning | 1 | 2025 | 73 | 0.890 |
Why?
| | Amphetamine-Related Disorders | 3 | 2015 | 48 | 0.880 |
Why?
| | Memory | 1 | 2025 | 295 | 0.770 |
Why?
| | Impulsive Behavior | 5 | 2019 | 146 | 0.760 |
Why?
| | Marijuana Abuse | 1 | 2025 | 211 | 0.710 |
Why?
| | Methamphetamine | 4 | 2019 | 70 | 0.710 |
Why?
| | Ventral Striatum | 1 | 2021 | 10 | 0.700 |
Why?
| | Cannabis | 2 | 2025 | 509 | 0.690 |
Why?
| | Suicide, Attempted | 2 | 2024 | 422 | 0.670 |
Why?
| | Narcotic Antagonists | 1 | 2023 | 205 | 0.670 |
Why?
| | Marijuana Use | 1 | 2025 | 213 | 0.670 |
Why?
| | Suicidal Ideation | 2 | 2024 | 577 | 0.660 |
Why?
| | Young Adult | 15 | 2026 | 14105 | 0.660 |
Why?
| | Sleep Wake Disorders | 1 | 2024 | 301 | 0.640 |
Why?
| | Schizophrenia | 1 | 2023 | 446 | 0.600 |
Why?
| | ROC Curve | 2 | 2019 | 614 | 0.580 |
Why?
| | Varenicline | 2 | 2016 | 28 | 0.580 |
Why?
| | Humans | 44 | 2026 | 144759 | 0.520 |
Why?
| | Machine Learning | 2 | 2024 | 585 | 0.510 |
Why?
| | Adult | 24 | 2026 | 40449 | 0.500 |
Why?
| | Antisocial Personality Disorder | 3 | 2013 | 121 | 0.500 |
Why?
| | Personality | 2 | 2015 | 132 | 0.490 |
Why?
| | Alcohol-Related Disorders | 1 | 2017 | 120 | 0.470 |
Why?
| | Facial Expression | 1 | 2016 | 74 | 0.460 |
Why?
| | Personality Tests | 1 | 2015 | 12 | 0.450 |
Why?
| | Neostriatum | 1 | 2015 | 37 | 0.440 |
Why?
| | Learning | 1 | 2019 | 452 | 0.430 |
Why?
| | Female | 26 | 2026 | 78271 | 0.390 |
Why?
| | Gyrus Cinguli | 1 | 2013 | 96 | 0.390 |
Why?
| | Male | 25 | 2026 | 72315 | 0.380 |
Why?
| | Adult Survivors of Child Abuse | 1 | 2013 | 32 | 0.370 |
Why?
| | Fear | 1 | 2016 | 366 | 0.370 |
Why?
| | GABA Uptake Inhibitors | 1 | 2011 | 5 | 0.350 |
Why?
| | Central Nervous System Stimulants | 1 | 2013 | 185 | 0.350 |
Why?
| | Nipecotic Acids | 1 | 2011 | 6 | 0.350 |
Why?
| | Psychopathology | 2 | 2023 | 56 | 0.340 |
Why?
| | Saliva | 1 | 2013 | 249 | 0.330 |
Why?
| | Decision Making | 3 | 2025 | 975 | 0.330 |
Why?
| | Hydrocortisone | 1 | 2013 | 304 | 0.330 |
Why?
| | Cognition | 1 | 2019 | 1266 | 0.320 |
Why?
| | Tryptamines | 1 | 2010 | 5 | 0.320 |
Why?
| | Serotonin Receptor Agonists | 1 | 2010 | 27 | 0.320 |
Why?
| | Oxazolidinones | 1 | 2010 | 17 | 0.320 |
Why?
| | Alprazolam | 1 | 2009 | 6 | 0.310 |
Why?
| | Game Theory | 1 | 2009 | 7 | 0.310 |
Why?
| | GABA Modulators | 1 | 2009 | 11 | 0.310 |
Why?
| | Adolescent | 7 | 2026 | 22428 | 0.300 |
Why?
| | Recurrence | 3 | 2019 | 1135 | 0.280 |
Why?
| | Motivation | 2 | 2024 | 610 | 0.270 |
Why?
| | Cues | 2 | 2021 | 326 | 0.270 |
Why?
| | Functional Neuroimaging | 2 | 2019 | 60 | 0.270 |
Why?
| | Pain | 1 | 2013 | 779 | 0.260 |
Why?
| | Sex Factors | 3 | 2025 | 2112 | 0.260 |
Why?
| | Endocannabinoids | 2 | 2018 | 57 | 0.260 |
Why?
| | Cross-Sectional Studies | 5 | 2025 | 5868 | 0.250 |
Why?
| | Cooperative Behavior | 1 | 2009 | 465 | 0.240 |
Why?
| | Interpersonal Relations | 1 | 2009 | 400 | 0.240 |
Why?
| | Double-Blind Method | 4 | 2016 | 2029 | 0.220 |
Why?
| | Self Administration | 4 | 2019 | 124 | 0.220 |
Why?
| | Photic Stimulation | 1 | 2026 | 264 | 0.220 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2947 | 0.210 |
Why?
| | Likelihood Functions | 2 | 2015 | 143 | 0.200 |
Why?
| | Connectome | 1 | 2025 | 95 | 0.200 |
Why?
| | Mental Recall | 1 | 2025 | 222 | 0.200 |
Why?
| | Receptors, Opioid | 1 | 2023 | 23 | 0.200 |
Why?
| | Anorexia Nervosa | 1 | 2024 | 79 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2011 | 2027 | 0.190 |
Why?
| | Nucleus Accumbens | 1 | 2024 | 132 | 0.190 |
Why?
| | Administration, Intravenous | 3 | 2018 | 170 | 0.180 |
Why?
| | Multivariate Analysis | 1 | 2026 | 1539 | 0.180 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1325 | 0.180 |
Why?
| | Oxygen | 2 | 2026 | 995 | 0.180 |
Why?
| | Naltrexone | 1 | 2023 | 117 | 0.180 |
Why?
| | Risk Factors | 4 | 2024 | 10779 | 0.170 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2026 | 780 | 0.170 |
Why?
| | Neuropsychological Tests | 3 | 2015 | 1134 | 0.170 |
Why?
| | Positron-Emission Tomography | 2 | 2019 | 323 | 0.160 |
Why?
| | Adolescent Behavior | 1 | 2025 | 501 | 0.160 |
Why?
| | Weight Gain | 1 | 2024 | 556 | 0.160 |
Why?
| | Child | 3 | 2024 | 22633 | 0.150 |
Why?
| | Central Nervous System Depressants | 2 | 2017 | 83 | 0.150 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2019 | 186 | 0.150 |
Why?
| | Substance Abuse Treatment Centers | 1 | 2020 | 49 | 0.150 |
Why?
| | Placebos | 2 | 2010 | 192 | 0.150 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2018 | 40 | 0.140 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2019 | 64 | 0.140 |
Why?
| | Violence | 2 | 2013 | 281 | 0.140 |
Why?
| | Punishment | 1 | 2018 | 20 | 0.140 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2018 | 39 | 0.140 |
Why?
| | Risk | 2 | 2019 | 911 | 0.140 |
Why?
| | Blood Alcohol Content | 1 | 2017 | 6 | 0.130 |
Why?
| | Nicotinic Agonists | 2 | 2016 | 136 | 0.130 |
Why?
| | Social Justice | 1 | 2018 | 86 | 0.130 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2024 | 675 | 0.130 |
Why?
| | Receptors, Opioid, mu | 1 | 2018 | 68 | 0.130 |
Why?
| | Pilot Projects | 1 | 2023 | 1886 | 0.130 |
Why?
| | Tobacco Use Disorder | 1 | 2019 | 218 | 0.130 |
Why?
| | Medical History Taking | 1 | 2017 | 117 | 0.130 |
Why?
| | Amidohydrolases | 1 | 2017 | 32 | 0.130 |
Why?
| | Nerve Net | 1 | 2019 | 285 | 0.120 |
Why?
| | Inpatients | 1 | 2020 | 545 | 0.110 |
Why?
| | Body Mass Index | 1 | 2024 | 2438 | 0.110 |
Why?
| | Alcohol Deterrents | 1 | 2015 | 26 | 0.110 |
Why?
| | Affect | 1 | 2018 | 318 | 0.110 |
Why?
| | Rest | 1 | 2015 | 124 | 0.110 |
Why?
| | Infusions, Intravenous | 1 | 2016 | 423 | 0.110 |
Why?
| | Analgesics, Opioid | 1 | 2023 | 1143 | 0.110 |
Why?
| | Functional Laterality | 1 | 2015 | 241 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 432 | 0.100 |
Why?
| | Self Report | 2 | 2016 | 872 | 0.100 |
Why?
| | Compulsive Behavior | 1 | 2013 | 6 | 0.100 |
Why?
| | Analysis of Variance | 2 | 2013 | 1306 | 0.100 |
Why?
| | Neural Pathways | 1 | 2015 | 311 | 0.100 |
Why?
| | Cohort Studies | 1 | 2024 | 5960 | 0.100 |
Why?
| | Comorbidity | 1 | 2018 | 1658 | 0.100 |
Why?
| | Logistic Models | 1 | 2019 | 2117 | 0.100 |
Why?
| | Exploratory Behavior | 1 | 2013 | 86 | 0.100 |
Why?
| | Models, Neurological | 1 | 2015 | 254 | 0.100 |
Why?
| | Psychological Tests | 1 | 2013 | 132 | 0.090 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2013 | 541 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2363 | 0.090 |
Why?
| | Animals | 5 | 2026 | 38058 | 0.090 |
Why?
| | Pituitary-Adrenal System | 1 | 2013 | 165 | 0.090 |
Why?
| | Pregnancy | 1 | 2024 | 7190 | 0.090 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2013 | 198 | 0.080 |
Why?
| | Patient Dropouts | 1 | 2011 | 65 | 0.080 |
Why?
| | Texas | 1 | 2011 | 278 | 0.080 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2011 | 232 | 0.080 |
Why?
| | Regression Analysis | 1 | 2013 | 1003 | 0.080 |
Why?
| | Survival Analysis | 1 | 2013 | 1382 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2024 | 5408 | 0.080 |
Why?
| | Breath Tests | 1 | 2010 | 79 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2115 | 0.080 |
Why?
| | Drug Synergism | 1 | 2010 | 357 | 0.070 |
Why?
| | Bayes Theorem | 1 | 2011 | 433 | 0.070 |
Why?
| | Middle Aged | 4 | 2020 | 35875 | 0.070 |
Why?
| | Anticonvulsants | 1 | 2011 | 235 | 0.070 |
Why?
| | Psychometrics | 1 | 2013 | 734 | 0.070 |
Why?
| | Fructose | 1 | 2009 | 130 | 0.070 |
Why?
| | United States | 1 | 2024 | 15966 | 0.060 |
Why?
| | Social Behavior | 1 | 2009 | 288 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6048 | 0.060 |
Why?
| | Prognosis | 1 | 2013 | 4282 | 0.050 |
Why?
| | Signal Transduction | 1 | 2018 | 5226 | 0.050 |
Why?
| | Genotype | 2 | 2018 | 1833 | 0.050 |
Why?
| | Prospective Studies | 1 | 2013 | 7990 | 0.040 |
Why?
| | Time Factors | 1 | 2011 | 7173 | 0.040 |
Why?
| | Gene Frequency | 1 | 2017 | 481 | 0.030 |
Why?
| | Anticipation, Psychological | 1 | 2015 | 20 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2017 | 340 | 0.030 |
Why?
| | Alleles | 1 | 2018 | 879 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 2015 | 280 | 0.020 |
Why?
| | Personality Inventory | 1 | 2013 | 134 | 0.020 |
Why?
| | Suicide | 1 | 2020 | 720 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 1406 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 2145 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 11679 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2925 | 0.020 |
Why?
| | Aged | 1 | 2020 | 25913 | 0.010 |
Why?
|
|
Gowin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|